During the past five years, research in the field of Factor Xa inhibitors has been marked with enormous efforts to identify highly potent, selective and orally-active agents. This research has led to the discovery of a number of clinical candidates that are currently progressing at different ...
The article presents a study which examines the safety and efficacy of oral anticoagulants compared to warfarin for stroke prevention in patients with atrial fibrillation. An overview of the ENGAGE AF-TIMI 48 trial of the use of the direct factor Xa inhibitor edoxaban is offered. Results of the...
In contrast, phospholipid had no effect on the affinity of Gla-domainless factor Xa for factor Va (Kd' = 4 X 10(-6) M). The maximal rate of thrombin formation increased approximately 300-fold with the addition of phospholipid to the factor Xa-factor Va system. Under the same conditions...
Assessing the efficacy and safety profiles of new oral direct Factor Xa (FXa) inhibiting anticoagulants compared with low-molecular-weight heparins (LMWHs) in elective total hip and knee arthroplasty (THA and TKA). The literature review only searched for randomised-controlled trials (RCTs) publishe...
In this prespecified subgroup analysis, we compared warfarin with edoxaban in patients with versus without previous IS/TIA.Methods—ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) was a double-blind trial of 21...
The Effective aNticoaGulation with factor xA next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48; clinicaltrials.gov identifier NCT00783191) trial is evaluating the efficacy and safety of edoxaban for stroke prevention in patients with atrial ...
Background and Purpose-The once-daily oral factor Xa inhibitor, edoxaban, is as effective as warfarin in preventing stroke and systemic embolism while decreasing bleeding in a phase III trial of patients with atrial fibrillation at moderate-high stroke risk. Limited data regarding cerebrovascular event...
Crystal structure of active site-inhibited human coagulation factor VIIa (des-Gla)<sup>1</sup> 1999, Journal of Structural Biology Show abstract Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant 1999, Journal of Molecular Biology Show abstract Factor VII...
Introduction: Andexanet alfa is a recombinant factor Xa decoy molecule that inhibits direct and indirect factor Xa inhibitors to allow the normal coagulation process to resume. Its development arises in a space where novel oral anticoagulants are receiving expanded indications yet their use is limited...
Factor Xa [1](Cell-free assay) Prothrombinase [1](Cell-free assay) 0.7 nM 2.1 nM In vitro In vitro Rivaroxaban is an oral, direct inhibitor of Factor Xa (FXa), being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban also inhi...